Introduction: The aim of the present study was to validate prothrombin time (PT) international normalized ratio (INR) results obtained using Steelex test reagents and a Steelex coagulometer (Steelex Scientifi c Instrument Company, Beijing, China), in comparison with use of a well-established standard test employing Pacifi c Hemostasis reagents (Fisher Diagnostics, Middletown, VA, USA) and Teco Coatron A4 coagulometer (Teco Medical Instruments GmbH, Neufahrn, Germany). Materials and methods: Between-and within-day coeffi cients of variation (CVs) of both assays were calculated using control samples provided by the test manufacturers. Samples from 90 subjects were collected and INR values were determined in a double-blind parallel manner employing both systems. 
Introduction
Prothrombin time (PT) is the most common coagulation test performed in the clinical laboratory. PT is used to detect abnormalities in the extrinsic coagulation pathway. PT measurement is critical when thrombotic patients are on oral anticoagulant therapy. However, it can be diffi cult to compare PT test results from diff erent laboratories (1); standardization is essential. Thromboplastin, the principal reagent of the PT assay, is commercially available in diff erent forms. To achieve the required standardization, all thromboplastin preparations should be calibrated using the International Sensitivity Index (ISI) and PT results should be presented in International Normalized Ratio (INR) units (2) . The WHO Expert Committee on Biological Standardization has decreed that standardization requires a comparison of results yielded by the test thromboplastin with those aff orded when a reference thromboplastin is employed (2, 3) . However, it is clear that standardization is not universally performed (4) (5) (6) (7) .
In Turkey, public procurement law requires that the lowest bid be accepted when equipment or reagents are ordered. Thus, the choice of a coagu- 
Materials and methods
The present study was conducted in the period from June to July 2011 in the clinical laboratory of the Şevket Yılmaz Research and Education Hospital. The study was approved by our institutional Ethics Committee and all participants gave written informed consent. All procedures were in accordance with the Second Declaration of Helsinki.
PT and INR determination methods
As a reference method, plasma PT was analyzed in an automated manner using a Teco Coatron A4 coagulator. The PT of citrated plasma was determined photometrically employing a high-resolution four-channel optic system (400 nm) and a suspension of rabbit brain thromboplastin (Thromboplastin-DS) prepared in calcium chloride solution.
The instrument was calibrated employing calibration reference plasmas with manufacturer-assigned INR values (TECal N calibration plasma cat. no. P800-010, Teco GmbH, Germany) (8) . The thromboplastin ISI value assigned by the manufacturer was 1.03. This is the method by which PT is routinely measured, in INR, in our hospital.
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The coeffi cients of variation of the regression line slopes of calibration curves of both instruments were less than 3%, in accordance with the WHO requirements (9). All INRs were calculated using a local prothrombin time (PT); this was the mean normal prothrombin time (MNPT) obtained using 20 fresh normal samples from healthy individuals (10).
Analytical precision of PT and INR determinations
Before specimen analysis, we performed two-level quality-control (QC) tests using materials supplied by either manufacturer (Steelex ANCP, catalog no. SS005711001 and NCP, catalog no. SS000500007; Pacifi c Hemostasis INR Control Plasma catalog nos. 100595 and 100596). Between-day diff erences in QC data were determined via analysis of duplicates on each of 20 successive days. Within-day precision was calculated by conducting 20 replicate analyses of the QC materials in a single run. Between-day precision is a measure of random analytical error (11).
Patients and blood sampling
Venous blood samples were obtained from 90 patients for whom PT (INR) tests were scheduled as part of routine preoperative check-up (N = 14) or for monitoring of oral anticoagulant therapy (OAT) (N = 76). Patients with atrial fi brillation and/or a prosthet-ic heart valve, and those prescribed long-term OAT were accepted to the study. Of all patients, 35 were in their fi rst 3 months of treatment (the dose-adjustment phase) whereas 41 were in a later treatment stage (the maintenance phase (2, 12) . Plasma was obtained via centrifugation for 15 min at 1,500 x g. All samples were assayed using the two systems within 1 hour of blood collection.
Statistical analysis
Data were evaluated using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and Analyse-It version 2.04 (Analyse-It Software, Leeds, UK). Means, standard deviations, and coeffi cients of variation were calculated. (13) (14) (15) .
Results
The coeffi cients of variation (CVs) of within-and between-day QC data are presented in Table 1 .
Passing and Bablok regression analysis yielded an intercept of 0.12 units (95% confi dence interval (CI) = -0.02-0.21) and a slope of 0.85 (95% CI = 0.79-0.91), suggesting that, a proportional diff erence existed between the two methods ( Figure 1) (14) . The cumulative sum linearity test (CUSUM test) revealed signifi cant deviation from linearity (P < 0.01) (14) .
The Bland-Altman diff erence plot showed that the mean bias was -0.156 units and the 95% limits of agreement were -0.912 to 0.600 when the Steelex and Pacifi c test data were compared (Figure 2) . The bias was lower in the sub-therapeutic range (INR < 2.0) and higher in the therapeutic range (INR = 2.0-4.5) (Figure 1 ).
Discussion
Extensive international collaboration has allowed laboratory INR measurement to become standardized worldwide; this is an essential feature of quality control (16, 17 
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We consider that the Pacifi c system is a suitable standard for use in validation studies as this method yielded acceptable quality control data during our study period and employs highly sensitive human thromboplastin (ISI = 1.03), as recommended by the College of American Pathologists (12).
Within-run imprecision was satisfactory for both systems (CV ≤ 3.1%). The Steelex system had a higher between-run CV than did the Pacifi c method, explained by the fact that use of reagents of higher ISI is associated with greater interlaboratory INR CVs (18) . The level of between-run imprecision using the Steelex system (Level 2; CV = 7.9%) was unacceptable; the value should be less than 5% when an INR assay is performed (19) .
Monitoring of PT via calculation of INRs is important for patients on oral anticoagulation therapy; appropriate doses can thus be prescribed. Accurate INR estimation is crucial (20) . Global harmonization of INR results, and agreement on the therapeutic ranges associated with varying clinical indications, is important (21). Many factors infl uence INR values; these include the levels of various coagulation factors present and their interaction with thromboplastin reagents diff ering in composition and sensitivity to the actions of such factors (22) . It can be diffi cult to obtain accurate and precise INR measurements. Both PT and INR data should be identical regardless of the reagents, instrument, or test method used. However, agreement among results yielded by many commercial INR methods is poor. Such variations may compromise patient care (1,7).
In our present work; Passing and Bablok regression analysis yielded the appropriate y-intercept value of zero but the slope of the regression line did not approximate unity, suggesting that, in addition to the presence of a small constant bias, a proportional diff erence existed between the two methods (14) . Our results are in agreement with previous fi ndings of poor agreement among data obtained using diff erent methods to calculate PT and INR (7, 23) . The variation noted in the present work may be attributable to diff erences between any or all of methodology, the coagulometers used, and thromboplastin source. bias relative to the consensus group. It provides a good measure of accuracy because each laboratory's results are compared to the mean value for all laboratories, which is assumed to be the true value.
and unpredictable eff ect on INR value (24) . The precision of PT testing tends to be greater when ISI is lower (24) but end-point reliability is also affected by reagent quality (24) .
Quality control is essential; it is recommended that analytical imprecision be less than or equal to half of intra-individual biological variation (25) (26) (27) (29) . In the present study, the overall analytical bias was indeed less than ± 0.2 INR units, but, in the therapeutic range, the bias was greater than ± 0.2 INR units, thus signifi cantly higher than current recommendations (28, 29) . It is evident that ISI strongly infl uences INR inter-laboratory variability (30) . Although the ISI assigned by the manufacturer of the Steelex M600H coagulometer was relatively low (1.18), a major limitation of our study is that local ISI calibration using WHO-certifi ed plasma was not performed. 
Conclusion
In conclusion, reliable PT, INR test data are important for proper management of patients on OAT.
Our results indicate that results obtained from Steelex M600H coagulometer using Steelex reagents kit are not interchangeable with Teco Coatron A4 coagulation coagulometer using Pacifi c Hemostasis reagent kit, in the therapeutic range.
